HealthCor Management’s NeoGenomics NEO Stock Holding History

HealthCor Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-391,110	Closed	-$3.37M	–	51
2022 Q3	$3.37M	Buy	+391,110	New	+$3.88M	0.42%	45

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HealthCor Management's NEO Position: Q4 2022 in Review

HealthCor Management sold out of NeoGenomics (NEO) in Q4 2022, closing a stake of 391,110 shares — an estimated $3.37M sold.

HealthCor Management first reported a position in NEO in Q3 2022 and held it in 1 quarter. The position peaked at $3.37M in Q3 2022. 244 funds tracked by Wall St. Rank hold NEO as of Q4 2022.

HealthCor Management reported no remaining NeoGenomics position as of Q4 2022 after selling out during the quarter.
HealthCor Management sold 391,110 NeoGenomics shares in Q4 2022, an estimated $3.37M.
HealthCor Management first reported a position in NeoGenomics in Q3 2022 and held it in 1 quarter.
HealthCor Management's NeoGenomics position peaked at $3.37M in Q3 2022.
244 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.